Sex |
|
Female |
9 (18.8%) |
Male |
39 (81.2%) |
Age, (years)* |
46.3 (12.8) |
On antiretroviral therapy |
48 (100%) |
InSTI |
34 (77.3%) |
NNRTI |
7 (15.9%) |
PI |
9 (20.4%) |
NRTI Backbone |
42 (87.5%) |
TDF-TAF/FTC-3TC |
26 (54.2%) |
ABC/FTC-3TC |
9 (18.8%) |
3TC-FTC |
7 (14.6%) |
Plasma HIV viral load (copies/mL) |
<20·0§
|
CD4+ T cell count per µL* |
798 (271) |
<350 per µL |
2 (4.17%) |
350-500 per µL |
5 (10.4%) |
>500 per µL |
41 (85.4%) |
CD4+ T cell count percentage* |
35.3 (14.35) |
CD4+ T/CD8 cells ratio |
0.98 (0.64) |
CD4+ T/CD8 ratio >=1 |
23 (47.9%) |
CD4+ T/CD8 ratio >=0·4 |
41 (85.4%) |
OIR |
19 (39.6%) |
HCV-Ab positive |
2 (4.2%) |
HBsAg positive |
2 (4.2%) |
CMV IgG positive |
27 (77.1%) |
Years since diagnosis |
6 (10) |
CD4+ T cell count per µL at nadir* |
254 (190) |
Plasma HIV viral load at zenith |
99692 (164664) |
AIDS diagnosis |
11 (22.9%) |
SARS-CoV-2 anti-N Ig positive |
7 (14.6%) |
VB in the preceding 12 months |
11 (22.9%) |